NCT04368403View on ClinicalTrials.gov

A Study of KHK4827 in Patients With Systemic Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

March 31, 2025

Conditions
Systemic Sclerosis
Interventions
DRUG

KHK4827

210 mg every 2 weeks (Q2W), subcutaneous (SC) injection

Trial Locations (1)

113-8655

The University of Tokyo Hospital, Bunkyo-ku

All Listed Sponsors
lead

Kyowa Kirin Co., Ltd.

INDUSTRY

NCT04368403 - A Study of KHK4827 in Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter